Receive The Newest Study Notifications

A breakthrough approach for treatment of autoimmune and inflammatory diseases THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF...

Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that BDD Pharma, the Company’s formulation partner in the area of Inflammatory Bowel Disease (IBD), has performed appropriate non-clinical...

Study Investigates Use of the Tack Endovascular System® for Focal Dissection Repair Following Drug-Coated Balloon Angioplasty in PAD Patients Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced...

CASI Pharmaceuticals, Inc. (CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, announces that the Chinese National Medical Product Administration (NMPA), the Chinese FDA, has accepted the...

Medality Medical LLC (“Medality” or the “Company”), a U.S.-based medical technology company, announced that it has received Institutional Review Board (IRB) approval from the University of Texas Health Science Center at San Antonio to commence human trials. Patient...

Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone (Kd) met its primary endpoint of progression-free survival...

Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced the dosing of the first Chinese patient in its on-going global pivotal Phase 3 trial of Xynomic’s abexinostat combined...

Discontinuation of studies based on Data Safety Monitoring Board recommendation Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today...

Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, announced today that its Phase 3 clinical trial of RP-G28 for lactose...

X-BOLT Orthopaedics, a leading medical device company, today announced preliminary results from the largest ever multi-centre randomised controlled trial comparing extracapsular hip fracture fixation devices, known as World Hip Trauma Evaluation 4 (WHITE4). The trial...

First Phase 3 Study Combining KYPROLIS and DARZALEX, Two Critical Mechanisms of Action in Treatment of Multiple Myeloma Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and...

 Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will present updated clinical results from the Phase 2b clinical trial of MDNA55 for the treatment of recurrent...

Sept. 12, 2019 13:07 UTC The 100+ site global Phase 3 clinical trial is the first-of-its-kind to leverage continuous multivariate wearable sensor data and Artificial Intelligence-based analytics The landmark trial endpoint approach aligns with commentary at a recent...

PALO ALTO, Calif., Sept. 12, 2019 /PRNewswire/ -- SightGlass Vision, Inc., a medical device company developing spectacle lenses to slow the progression of nearsightedness or myopia in children, today announced that baseline data from CYPRESS, the Company's pivotal...

Combination of Novel Gene Therapy and Immunotherapy Being Evaluated for Synergistic Anti-Tumor Activity in Patients with Cancer with Limited Treatment Options Okayama, Japan, (GLOBE NEWSWIRE) - Momotaro-Gene, a clinical-stage biotherapeutics company developing novel...

The University of Kansas Cancer Center and Midwest Cancer Alliance have been awarded a grant to expand the reach of cancer clinical trials to Kansas’ rural communities. The six-year grant designates the team as a minority/underserved (MU) community site of...

Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3 clinical trial of...

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Toca 5 Phase 3, randomized, multi-center clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) undergoing...

When it comes to recruitment, LinkedIn has become one of the best tools businesses can use to attract and bring in quality talent. For patient recruitment companies, the same holds true for bringing in potential patients for clinical trials. However, when it comes to...

Concert Pharmaceuticals, Inc. (CNCE) today announced that it will present results from its recently completed Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. These data will be presented in the late breaking news session at the European...